Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025HaematologicaOpen Access

Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide

View Full Paper
Ask AI
Bookmark
Share

Authors

MVMarta VillalbaJMJuan MontoroABAitana Balaguer‐Roselló

Discussion

Loading...

Member takes

Overview

Observational analysis reveals significant variations in overall survival among AML patients, suggesting new genetic insights.

Key Points

  • Identifying distinct genetic risk categories enhances overall survival predictions in AML patients after transplantation.
  • The study found a 2-year overall survival rate of 77%, indicating substantial survival potential with appropriate risk stratification.
  • Assessment based on the newly defined risk categories indicated that adverse risk patients had an HR of 4.24, highlighting the serious implications of genetic factors.
  • Incorporating minimal residual disease status effectively refined risk classification, aligning certain high-risk patients with standard-risk outcomes.

Cite This Study

Villalba et al. (2025) studied this question.

synapsesocial.com/papers/68c23bd7b210217d64787039https://doi.org/10.3324/haematol.2025.287860
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Performance of the ELN 2022 risk stratification in a real-world Canadian AML patient population2025
  2. 2TP53, EZH2, or RUNX1 mutations predict poor outcomes in ELN 2022 adverse risk group of adult AML patients undergoing allo-HSCT2025
  3. 3Prognostic evaluation of ELN-2022 and ELN-2024 risk stratification in newly diagnosed AML patients and development of a novel genetic risk model2025
  4. 4Risk stratification of newly diagnosed AML receiving nonintensive treatment2025
  5. 5Impact of induction response and co-mutations on transplant outcomes in AML with myelodysplasia-related gene mutations: A multicenter retrospective study2025